About the Company
actinium pharmaceuticals, inc. (www.actiniumpharma.com) (nyse mkt: atnm) is a new york-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. actinium's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. the company’s lead radiopharmaceutical iomab™-b will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. the company is preparing a single, pivotal, multicenter phase 3 clinical study of iomab™-b in refractory and relapsed acute myeloid leukemia (aml) patients over the age of 55 with a primary endpoint of durable complete remission. the company’s second program, actimab-a, is continuing its clinical development in a phase 1/2 trial for newly diagnosed aml patients o
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ATNM News
Actinium Pharmaceuticals Inc ATNM
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Actinium Pharma Stock (AMEX:ATNM), Analyst Ratings, Price Targets, Predictions
Actinium Pharmaceuticals Inc has a consensus price target of $24.8, established from looking at the 21 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co ...
Actinium Pharma Stock (AMEX:ATNM), Quotes and News Summary
What's Going On With Actinium Pharmaceuticals Stock? Actinium Pharmaceuticals Inc (AMEX:ATNM) shares are trading higher Tuesday after the company announced full data results from the pivotal ...
Actinium Says Phase 3 SIERRA Trial Results Of Iomab-B Shows Improving OS For AML Patients
Actinium Pharmaceuticals, Inc. (ATNM) announced Thursday that results from the Phase 3 SIERRA trial of Iomab-B were presented in an ...
Actinium Pharmaceuticals: Strong Buy Rating on Financial Health and Promising Pipeline
Actinium Pharmaceuticals (ATNM) Company Description: Actinium Pharmaceuticals, Inc. is a clinical-stage, Biopharmaceutical Company focused on developing and potentially commercializing therapies ...
Wall Street Bulls Eye a 290% Upside on Actinium Pharmaceuticals, Inc. Amidst Groundbreaking Cancer Therapy Innovations
Stay tuned for updates on this exciting journey, as Actinium Pharmaceuticals continues to redefine the landscape of cancer treatment and cellular therapy. On Friday, Ginkgo Bioworks Holdings, Inc ...
Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel targeted therapies. It also develops and markets medicines for relapsed or ...
Actinium Pharmaceuticals Inc ATNM
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Actinium Pharmaceuticals Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Loading the latest forecasts...